LDN-193189 (LDN193189, DM3189, DM-3189) 2HCl，是一种选择性BMP信号抑制剂，抑制ALK1/2/3/6，IC₅₀分别为0.8 nM、0.8 nM、5.3 nM和16.7 nM。LDN-193189已被用于研究进行性骨化性纤维发育不良的发病机制、先天性骨化障碍和骨形成在前列腺肿瘤骨转移中的作用。

参考文献

1.Yu PB, et al. BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat Med. 2008 Dec;14(12):1363-9.

2.Cannon JE, et al. Intersegmental vessel formation in zebrafish: requirement for VEGF but not BMP signalling revealed by selective and non-selective BMP antagonists. Br J Pharmacol. 2010 Sep;161(1):140-9.

3.Lee YC, et al. BMP4 promotes prostate tumor growth in bone through osteogenesis. Cancer Res. 2011 Aug 1;71(15):5194-203.

4.Derwall M, et al. Inhibition of bone morphogenetic protein signaling reduces vascular calcification and atherosclerosis. Arterioscler Thromb Vasc Biol. 2012 Mar;32(3):613-22.

冰袋运输。粉末直接保存于-20℃，有效期3年。建议分装后-20℃干燥保存，避免反复冻融。